CEMP Profile
CEMP
or Cempra, Inc. is a pharmaceutical company that develops and
commercializes antibiotics for acute bacterial infectious diseases.
The company was founded in 2006 and is headquartered in Chapel Hill,
North Carolina.
CEMP has a number of products in its pipeline,
including solithromycin, a novel macrolide antibiotic for the
treatment of community-acquired bacterial pneumonia (CABP), and
fusidic acid, a topical antibiotic for the treatment of impetigo.
In addition to its product pipeline, CEMP has partnerships with
various organizations to further its research and development efforts.
The company has a collaboration agreement with Optimer Pharmaceuticals
for the development of certain antibiotics, and it has also partnered
with the Biomedical Advanced Research and Development Authority
(BARDA) to develop antibiotics for biodefense and emerging infectious
diseases.
Despite the potential of its pipeline products, CEMP
has faced some setbacks in recent years. In December 2016, the company
announced that the U.S. Food and Drug Administration (FDA) had issued
a Complete Response Letter (CRL) for solithromycin. The FDA requested
additional safety and efficacy data for the drug, delaying its
potential approval.
CEMP's stock price has fluctuated
significantly in response to these developments, and investors should
be aware of the risks associated with investing in pharmaceutical
companies, particularly those in the early stages of drug development.
Overall, CEMP's focus on developing novel antibiotics for
infectious diseases is an important area of research, and if the
company can successfully navigate the regulatory hurdles, its products
could have a significant impact on public health. However, investors
should carefully consider the risks associated with investing in a
company in the pharmaceutical industry, particularly given the
uncertainty surrounding FDA approval
|
